RESEARCH DOSSIER
Insurance Internal Model Approval and Regulatory Validation
Abstract. Insurance internal-model approval is a legal authorization to calculate prescribed solvency capital by using an insurer-specific quantitative representation of its risks. The authorization joins probability modeling to governance, reporting, financial measurement and continuous supervisory oversight. This monograph reconstructs the structure of that authorization under the European Union's Solvency II regime, evaluates its statistical and institutional foundations, and compares the approach with the United Kingdom's Solvency UK permissions regime, the United States' state risk-based capital arrangements and the International Association of Insurance Supervisors' global standards. Its principal finding is that internal-model validity is an ongoing, evidence-bearing institutional judgment: the modeled loss distribution, its correspondence with the insurer's economic balance sheet, actual use by management, reproducible documentation, independently challenged assumptions and enforceable change controls must remain mutually consistent. Regulatory approval is therefore a conditional and revisable authorization with a defined legal perimeter. A tail-quantile calculation alone cannot demonstrate that a model is prudentially fit. Formal illustrations show the contribution of dependence assumptions to capital, the sparse statistical information inherent in the 99.5% annual quantile, and why financial profit-and-loss attribution and reverse stress testing are essential complements to statistical backtesting. The research distinguishes rules applicable on November 14, 2026 from the European amendments scheduled to apply on January 30, 2027. The contribution is a documented analytical synthesis, not a proposed new regulatory doctrine or empirical estimate.
Keywords: Insurance internal model; supervisory approval; regulatory validation; Solvency II; Solvency UK; solvency capital requirement; probability distribution forecast; use test; statistical quality; calibration; profit and loss attribution; model change policy; insurance group supervision; tail risk; regulatory capital; independent validation.
Introduction: The Regulatory Object
The object of internal-model authorization is the legitimacy of a particular method for calculating a legal capital requirement for a particular insurer or insurance group. An internal model may be an excellent forecasting system for underwriting or investment management and still fail the tests required for calculating a regulatory solvency capital requirement (SCR). The reason is the difference in the decision at issue. Pricing asks which premium is compatible with anticipated losses, expenses and commercial objectives. Reinsurance optimization asks which transfer structure improves the insurer's risk-return position. Prudential capital asks how much loss-absorbing financial capacity is required under a prescribed legal measure of risk. These activities share models, data and experts, but their objectives, accounting boundaries, horizons and error costs differ.
The European regime specifies the SCR in Article 101's one-year calibration as a Value-at-Risk (VaR) of basic own funds at a confidence level of 99.5%. In its simplest financial interpretation, an insurer must model adverse changes in eligible capital-relevant resources under a one-year distribution that reflects all material quantifiable risks. The legal definition concerns basic own funds and the full solvency calculation; a stand-alone claims-loss VaR generally measures a different object. Prudential adequacy also depends on how technical provisions, assets, liability options, reinsurance recoveries and foreseeable business affect the loss distribution.
Internal models matter because portfolios differ. A multinational life group with guarantees and interest-rate exposures, a specialist reinsurer absorbing catastrophe concentrations, and a regional non-life carrier exposed to claims inflation all combine risks differently. EIOPA's internal-models overview recognizes models as tools for both SCR calculation and forward-looking business decisions. Their discriminatory power depends on the quality of a firm's risk mapping, the fit of economic and actuarial assumptions, and the discipline with which uncertainties are communicated.
The scientific question is consequently twofold: what grounds a rational belief in a model's capital numbers, and what organizational and legal evidence allows the supervisor to authorize the model's use? These questions can be studied jointly without conflating the supervisor with an academic peer reviewer. The supervisor makes a legally operative decision under a statutory mandate; an academic researcher evaluates how evidence supports that decision and what its limitations entail.
The methods here are textual interpretation of verified primary insurance rules; comparative institutional analysis; reconstruction of distributional and balance-sheet relationships; small explicitly hypothetical numerical calculations; and a critical reading of established interval-forecast testing scholarship. Claims are stated with the jurisdiction and regulatory version to which they belong. No proprietary insurer model, confidential supervisory application or insurer-level validation dataset is used. Quantitative illustrations test internal logical relationships rather than estimate any company's actual capital.
Internal Model Authorization and Legal Perimeter
Authorization as a bounded permission
Solvency II Article 112 approval requirements permit full or partial models and require evidence of compliance with Articles 120–125. The supervisor decides within six months after receipt of a complete application. The regulatory permission governs a defined scope and a defined effective date. It should not be interpreted as a certificate that every parameter will remain accurate under all future conditions. Authorization turns on a judgment that the insurer's risk-identification, measurement, monitoring, management and reporting systems are adequate and that the model meets relevant quality standards.
The distinction between full and partial models is substantive. A full model addresses the prescribed SCR across the approved risk perimeter; a partial model may cover modules, submodules, business units or the other areas permitted by the directive. Article 113's partial-model conditions require justification of the limited scope, an improved representation of the risk profile, and a defensible connection to the remainder of the standard formula. Partiality creates a boundary problem: dependencies, offsets and aggregation conventions at the interface can determine the capital outcome as much as the modeled component.
Application dossier and procedural sequence
Implementing Regulation 2015/460 requires a written application and specified documentary evidence, including a description of scope, history of model use, data and assumptions, validation, governance and board approval. Its Article 3 provides a 30-day completeness determination. If the application is incomplete, the six-month substantive decision period has not begun. If it is complete, the six-month period runs from receipt of that complete application; additional information can still be requested during the assessment. The application procedure therefore contains an entry screening and a substantive judgment with different legal purposes.
A sound application starts with an inventory of risk exposures and establishes traceability from exposure classes to datasets, actuarial assumptions, modeled events, projected economic balance sheets and calculated SCR. Documents should identify who owns every relevant decision. Where external catastrophe models, ESG datasets, credit assessments or stochastic economic-scenario generators supply inputs, the insurer must document their roles and limitations. A technically polished model interface cannot compensate for an undocumented change in catastrophe vulnerability, reinsurance attachment or asset credit migration.
Article 243's documentation requirement makes the expected level of reproducibility particularly concrete: a knowledgeable independent third party must be able to understand and appraise the design and operation, and outputs must be reproducible from model documentation and inputs. This requirement is an evidentiary condition. It does not demand disclosure of every commercial detail to the public, but it requires controlled access, data lineage and method transparency sufficient for a supervisory review.
What the approval decision establishes
An authorization establishes the permissibility of the approved calculation approach under the relevant regime and conditions. The model's statistical specification, firm use and governance are jointly necessary elements. Its conditional character becomes explicit in Articles 115–119 of Solvency II: changes are classified under an approved change policy, major changes require prior approval, and material failure to comply can lead to restoration plans or reversion to the standard formula. Model approval is therefore a monitored legal relationship rather than a one-time assessment of a software artifact.
The Use Test, Governance, and Institutional Accountability
Decision usefulness and prudential credibility
The Article 120 use test requires extensive, material use of the model in governance, risk management, decision-making and economic and solvency capital assessment or allocation. Calculation frequency must correspond to the frequency of use for these purposes. The administrative, management or supervisory body (AMSB) must ensure continuing appropriateness. These conditions discourage a parallel 'regulatory-only' calculation that is disconnected from the firm's real decisions.
The decisive question is the causal role of model information in governance. A model may appear on a board dashboard and yet exert little influence if investment limits, underwriting capacity and reinsurance purchasing continue to follow unrelated measures. Conversely, a capital model may contribute meaningfully through scenario analyses, risk appetite metrics, capital attribution and pre-transaction risk assessments even when specific commercial decisions use additional information. The test concerns demonstrated integration and credible explanation, rather than mechanical identity among all risk measures.
Evidence may consist of dated investment committee materials, underwriting authorities, risk-limit calibration, documentation of reinsurance purchases, decisions after model exceptions, ORSA assessments and records of board challenge. The model's contribution should be legible: what alternatives were considered, which modeled outcomes altered the decision and which limitations were communicated? After-the-fact declarations of usefulness have weaker evidential force than contemporaneous decision records.
Board understanding and ownership
Governance is most demanding where technical expertise is concentrated in a small specialist team. Senior management can delegate computation but retains accountability for the risk decisions. The PRA's SS17/16 expectations highlight the role of directors, model justification and validation. A board that receives only a single SCR number cannot interrogate the dependency structure, sensitivity to risk factors, treatment of guarantees or scope of model exclusions.
Effective challenge requires a layered explanation: model architecture in business language, quantified sensitivities for material assumptions, a register of known weaknesses, governance implications and transparent reporting of items whose effects are incompletely measured. Technical teams retain responsibility for equations, code and data; the governing body needs enough understanding to judge material consequences and require corrective action. The strongest record is an auditable sequence of questions, responses and follow-up decisions, not an assertion that the board has 'reviewed' a completed presentation.
Independence without institutional isolation
Validation independence means effective freedom to challenge development decisions, assumptions and performance. Delegated Regulation Article 241 explicitly addresses influence from model developers and operators and calls for evaluation of internal responsibilities or external remuneration and mandates. Independence can be protected through separate reporting lines, accountable committee escalation, the right to reopen assumptions and freedom to flag material unresolved concerns. It does not require validators to work without the quantitative expertise and operational access necessary to understand the model.
A useful governance distinction arises between model ownership and acceptance of residual uncertainty. Developers own implementation and explanation; validation examines the strength of evidence; management judges the business implications within its risk appetite; and the supervisor decides whether prescribed authorization conditions are met. Documentation should preserve these decision rights, including disagreements and their resolution.
Statistical Quality, Risk Distributions, and Calibration
Economic quantity and distributional representation
Let denote basic own funds at inception and their value after one year under a modeled state. Define a stylized economic loss . Then a simplified VaR expression is , with . This is an analytical restatement and not a substitute for the directive's complete balance-sheet and going-concern specification. The symbol 'approximately' captures the need to reconcile all regulatory valuation and aggregation rules.
The Article 121 statistical quality standards require actuarially and statistically adequate techniques, current credible information, realistic assumptions and accurate, complete, appropriate data, updated at least annually. Forecasts should represent more than the central tendency of ordinary claims. Insurance capital may depend on loss-event frequency and severity, reserve deterioration, market shocks, longevity or mortality changes, policyholder behavior, credit migration, liquidity-induced asset disposals and interactions among them.
Data adequacy is relational. A million historical motor claims cannot automatically validate the tail of a new cyber portfolio, and an external catastrophe event set cannot be treated as observed annual frequency data without considering event-generation and vulnerability modeling. The validation question is whether the selected information is relevant to the insured exposures, policy terms, inflation regime, geographical concentrations and loss settlement process.
Illustrative capital calibration
For a deliberately simplified numerical example, suppose a stylized annual economic loss, measured in millions of currency units, is normally distributed with mean and standard deviation . The 99.5th-percentile standard-normal quantile is approximately . The model therefore gives . This result illustrates a distributional calculation, not an insurer's lawful SCR. The assumed normal tail, loss definition, dependence structure, management actions, new business and tax or valuation effects would all require separate examination in a genuine application.
Even in this simplified setting, a single quantile conceals consequential assumptions. A heavier-than-normal catastrophe tail may change the 99.5th percentile materially despite leaving variance comparatively stable. A climate-conditioned exposure shift may undermine stationarity, and reverse stress testing may disclose scenarios threatening the business that do not sit near the modeled quantile. Model selection is therefore part of prudential judgment.
The Article 122 calibration rules permit alternative time horizons or risk measures for internal purposes only if the SCR can be derived to provide equivalent policyholder protection. Supervisors may require benchmark portfolios and external assumptions to test calibration. For a model that internally uses expected shortfall, multi-year projections or a risk appetite statistic, the conversion to the prescribed one-year SCR must be explained and tested. Merely applying a scaling factor without a defensible treatment of temporal dependence, contract options and changing exposures would leave the equivalence claim unresolved.
Dependence and diversification
Consider two hypothetical risk losses with standard deviations 100 and 80 million, each with mean zero. Under a bivariate normal illustration with correlation , the standard deviation of the sum is . If , it is approximately , giving a 99.5th-percentile loss of about million. If , it is approximately , giving approximately million. The stand-alone sum is about million. A change in dependence assumptions, with both marginal volatilities held fixed, alters modeled capital by over 100 million. All figures are calculations from stated hypothetical assumptions and are rounded.
These results do not validate a Gaussian dependence structure. In financial crises, catastrophe clusters or counterparty defaults, adverse events may coincide in ways that linear correlation fitted to ordinary periods understates. The prudential concern is joint tail behavior and the stability of purported diversification under changing economic conditions. The EIOPA comparative-studies program provides an institutional mechanism for benchmarking market, credit, underwriting and diversification modeling across firms, complementing firm-specific scrutiny. Benchmark results need to be read alongside portfolio composition and approved scope; dispersion alone is not proof that one insurer is wrong.
Parameter and simulation uncertainty
If independent one-year outcomes each had a true 0.5% probability of exceeding the modeled 99.5th-percentile threshold, twenty observed years would yield an expected 0.1 exceedances. The probability of observing none would be . Thus twenty years without an exceedance provide weak evidence for tail calibration even under idealized independence and stationarity. The analogy becomes less informative when economic regimes, portfolio mix and data methods change.
Simulation noise adds another difficulty. In 10,000 independent simulated scenarios, only about 50 would fall above the 99.5th-percentile threshold on average. Tail estimates can respond sharply to random seed, scenario-generation choices, nested valuation approximations and rare-event treatment. Validation should therefore quantify numerical stability as well as uncertainty about physical and economic distributions. More runs reduce Monte Carlo error conditional on the model; they cannot repair a misspecified catastrophe mechanism or incorrect reinsurance contract coding.
Profit and Loss Attribution and Economic Interpretation
Explaining realized changes
Article 123's profit-and-loss attribution requires insurers at least annually to investigate major business-unit profit-and-loss sources and demonstrate how their model risk categories explain them. Its scientific purpose is the compatibility of modeled causal accounting with experienced economic outcomes. The categories may distinguish interest rates, credit spreads, mortality, morbidity, lapse, claims development, catastrophe events, expenses, foreign exchange and the effects of financial or contractual management actions.
An attribution exercise needs a transparent bridge between opening and closing balance sheets. Illustratively, changes in own funds can be decomposed into modeled market effects, insurance experience, assumption and method updates, new business, capital transactions and residual or unexplained items. The decomposition is path- and method-dependent: interactions cannot always be allocated uniquely to a single cause. Attribution therefore requires documented ordering, treatment of interactions and separate disclosure of residuals.
The importance of residuals rises when model outputs have legal consequences. A large unexplained profit or loss may indicate missing risks, valuation mismatches, timing differences, incorrect data mappings, parameter drift or choices in the attribution algorithm. It does not by itself identify which cause is responsible. A disciplined investigation starts with reconciliation to financial and actuarial records, distinguishes technical noise from genuine risk explanations, and assesses whether the SCR forecast remains credible.
P&L attribution and backtesting are complementary
Backtesting a probability threshold asks whether observed exceptions agree with a modeled frequency. Profit-and-loss attribution asks whether the mechanisms modeled correspond to actual movements in solvency resources. A model can pass a crude exception count while getting its explanation wrong, for example by offsetting underestimated lapse losses with overestimated market volatility. Equally, a good attribution of common movements cannot establish the accuracy of an extremely rare tail.
The connection is made operational in Article 242's validation tools, which require comparisons between model results, experience and P&L attribution, including tests at individual and aggregated levels. Quantile calibration should be examined together with explanatory components, stress scenarios and diagnostics of model specification. This is especially important when one-year aggregate economic loss data contain too few tail observations to discriminate among models.
Business-unit and group reconciliation
For a multi-line insurer, risk-category definitions and accounting units may be inconsistent. A life business may measure guarantee sensitivities on an economic value basis, while a non-life unit tracks accident-year loss development, and a central treasury computes credit exposures. A credible model requires an explicit mapping between these systems. Reinsurance recoveries, intra-group risk transfer and changes in asset backing must be treated so that gains and losses are not double-counted.
An analytically useful distinction is between accounting reconciliation, economic explanation and prudential calibration. Accounting reconciliation establishes that measured movements match the records. Economic explanation assigns plausible drivers and material interactions. Prudential calibration assesses whether the chosen distribution of future changes produces the prescribed protection level. The three checks operate on different evidence and should be reported separately.
Validation, Independent Challenge, and Model Uncertainty
Validation as an ongoing test program
Solvency II Article 124 establishes a regular validation cycle, including performance monitoring, assessment of specification, comparison with experience, assessment of stability and sensitivity, and review of data accuracy, completeness and appropriateness. Validation is not complete when a codebase is shown to reproduce its own outputs: numerical correctness, assumption credibility, exposure completeness and relevance to regulatory capital all matter.
Article 241's independent-review safeguards require the validation process to cover all parts of an internal model and specify tasks, validation frequencies, triggers for extra review, responsibilities and procedures when problems are identified. This supports a risk-proportionate schedule. Rapid exposure growth, an acquisition, a new reinsurance structure, a stress-period data break, a material regulatory change or repeated attribution residuals may warrant immediate revalidation instead of awaiting the next annual cycle.
A comprehensive evaluation should test: input reconciliation and data lineage; mathematical consistency; implementation accuracy; parameter estimation and uncertainty; forecast specification and tail assumptions; aggregation; reinsurance and management actions; operational resilience; model use; and compliance with the approval scope. Each test should record a purpose, a falsifiable expectation, its observed result, limitations, responsible reviewer and remediation status. The point is traceable challenge rather than decorative accumulation of test counts.
Coverage, conditional behavior, and rare events
Kupiec's (1995) VaR testing supplies a standard route to examining unconditional exception frequencies. Christoffersen's (1998) conditional-coverage analysis shows why the clustering and dependence of interval exceptions matter in addition to their number. These methods were developed in financial risk and forecasting settings and can inform insurer model validation, provided their observational assumptions are assessed rather than silently carried over.
Annual insurance SCR backtests are especially weak as stand-alone tests because the 0.5% target event is rare, available independent annual outcomes are few, and the insurer's portfolio and model may change between observations. More frequent proxy tests can reveal parameter or component failures, but a monthly or daily metric is not automatically an exact test of the prescribed one-year total-balance-sheet quantile. An effective validation plan uses several complementary resolutions: frequent component backtests, aggregate sensitivity tests, plausibility against external events and controls over distributional extrapolation.
Reverse stress tests and failure mechanisms
Article 242's reverse-stress requirement calls for identifying the most probable stresses that would threaten the insurer's viability. Starting with a failure condition changes the analytical question. Instead of asking how much loss occurs at a chosen probability level, the study asks which combinations of shocks could breach critical capital, liquidity or operational thresholds and how plausible those combinations are.
Examples include simultaneous insurance losses and reinsurance-counterparty distress; credit spreads rising while policyholder lapse accelerates; a severe catastrophe coinciding with collateral calls; claims inflation exceeding the assumptions underlying reserves; or a technological outage that undermines both claims operations and timely reporting. A model can approximate each component but fail to represent the joint process. Reverse stress testing directs attention to structural omissions and interdependencies that a single reported SCR number does not reveal.
Data, vendors, and reproducibility
Article 244's documentation inventory requires information about data sources, assumptions, model components, validation and external data or models. An external vendor's proprietary algorithm creates a particular governance problem: the insurer remains accountable for a regulatory output although it may have restricted access to implementation details. Independent challenge therefore requires contractually available technical evidence, known limitations, version controls, benchmarking and fallback procedures adequate for material decisions.
Reproducibility should identify the exact source data extract, exposure snapshot, valuation assumptions, code version, random seeds, scenario libraries, parameter tables and capital aggregation settings. Where a full run cannot be replicated cheaply, reproducibility may be established through controlled sampling and reconciled intermediate outputs, with the remaining uncertainty disclosed. Recordkeeping is central to both internal review and later supervisory reconstruction.
The boundaries of validation evidence
A high p-value on a model test is weak evidence when the test lacks power, the sample is small or the model has been repeatedly re-tuned using the same evaluation set. Passing performance on ordinary periods says little about changes in catastrophe vulnerability or the behavior of guarantees near financial distress. Cross-validation and out-of-sample evaluation are useful only when the split respects time, exposure development and event dependence. Tests of hypothetical scenarios need transparent assumptions and cannot be represented as observed empirical success.
The evidence standard should match the materiality and failure consequences of the model component. An immaterial expense submodel and a highly leveraged guarantee exposure do not require identical testing effort. At the same time, the total model may contain several individually minor uncertainties that combine into a material capital distortion. Validation must examine aggregation as well as component judgments.
Partial Models, Group Models, and International Comparison
Partial-model interfaces
Under Article 113's integration criteria, a partial model requires a defensible boundary and integration with the standard formula. The interface determines which diversification effects are recognized and whether risk is counted twice or omitted. Suppose a custom catastrophe module changes the loss distribution while its connection to credit risk uses an unchanged standard-formula dependency assumption. The result may appear more tailored, yet miss the dependency between catastrophe claims and reinsurer defaults. Evidence must address the interface itself, including stress behavior and the scope of unmodeled risks.
A phased extension plan may be required in circumstances contemplated by Article 113. Such a plan should identify covered business units, data and governance requirements, implementation stages and objective decision gates. The analytical reason is comparability: without a traceable boundary, a reported reduction in SCR could arise from a true change in risk information, a different aggregation convention or a gap in coverage.
Insurance groups
Group internal-model assessments face differences in legal entities, currencies, supervisory jurisdictions, fungibility and transferability of capital and risk concentrations. The insurer group may have a single economic-risk perspective, while regulatory constraints restrict moving capital or liquidity across subsidiaries. Group capital therefore requires attention to intragroup exposures, reinsurance, concentration and consistency of assumptions across entities.
The IAIS Insurance Core Principles and ComFrame place capital adequacy within a broader system of enterprise risk management, solvency assessment and supervisory oversight. These international standards establish a common vocabulary and supervisory expectation, while legally operative approval comes through the relevant domestic framework. They should not be mistaken for a single global permission to use an internal model.
The 2026 EIOPA group-solvency guidance demonstrates a temporal issue for group analysis: new guidance is adopted before it applies. The revised guidelines are scheduled for January 30, 2027; the earlier guidelines continue to govern until then. A group-level model review dated November 2026 should therefore map current law and forthcoming requirements in distinct columns.
United Kingdom: a related but separate regime
The UK PRA sets out its model-permission and continuing-monitoring approach in SoP3/24 on internal-model permissions, current November 2024 version, effective December 31, 2024. It addresses applications, variations for major changes, safeguards where residual limitations remain, treatment of material standard-formula differences and continuous review. SS1/24 on validation expectations clarifies PRA expectations for data, model validation, documentation, limitations and changes. These are UK regulatory instruments and should be attributed to the PRA rather than presented as automatically governing an EU-authorized firm.
The comparison is informative because both systems connect insurer-specific solvency modeling with institutional oversight, yet differ in their legal implementation and decision architecture. A technical modeling approach acceptable for one application cannot be presumed approved for another legal entity or supervisor. Transferability requires a documented mapping between the approved perimeter, governing rules and current insurer exposures.
United States: statutory RBC rather than EU-style approval
NAIC's risk-based capital explanation describes U.S. RBC as a statutory threshold framework reflecting insurer size and the riskiness of assets and operations, designed to identify undercapitalized insurers and guide supervisory action. It is not an insurer ranking tool. U.S. state-based regulatory capital cannot be described as a single EU-style full/partial internal-model authorization procedure. Insurers may use sophisticated economic capital and stochastic models for management and for particular statutory purposes, but the legal recognition of any such work depends on the specific state-based requirements.
The substantive comparison concerns objectives. A prescribed formula supports consistency and action thresholds; a firm-specific approved model can offer richer representation at the cost of greater governance and validation demands. Neither approach is rendered universally superior by definition. An appraisal should ask how materially different exposures are treated, how model uncertainty affects protection of policyholders, and how quickly supervisors can act on weaknesses.
International standards and local authority
The IAIS ICP 16 and ICP 17 standards connect enterprise risk management, own risk and solvency assessments and capital adequacy. Their comparative value is the attention paid to governance, forward-looking risk assessment and the total balance sheet. Their normative reach must still be distinguished from national law, statutory permissions and supervisory decisions. Cross-jurisdictional analysis should preserve the level of instrument: statute, delegated regulation, supervisory policy, guidance, soft-law standard or insurer internal policy.
Model Changes, Supervisory Intervention, and the 2027 Transition
Change governance after approval
The model used a year after permission may differ in exposure data, code, scenario distribution, risk taxonomy or aggregation. Solvency II's model-change policy requires the initial approved policy to distinguish major from minor changes. Major changes and changes to the policy itself require prior supervisory approval. Minor changes may proceed under the approved policy. The classification of combinations matters: a sequence of individually minor updates can alter a model materially.
Change assessment must therefore consider cumulative effects and correlations among changes. A revised economic scenario generator could alter market risk, the valuation of options and the effect of management actions simultaneously. A revised catastrophe vulnerability function could affect reinsurance attachment probabilities and the perceived diversification of risks. Governance should compare the model before and after the change under common exposures, describe affected outputs and disclose the sensitivity of capital to the revision.
Supervisory response to deficiencies
Articles 117–119 supervisory powers govern justified reversion to the standard formula, failure to meet internal-model requirements and significant departures from assumptions underlying the standard formula. Under Article 118, an insurer that ceases to comply must promptly provide a plan to restore compliance within a reasonable period or demonstrate that the effect is immaterial. Failure to implement the plan can lead the supervisor to require the standard formula. Such intervention makes a model's weaknesses consequential for capital, governance and strategic decisions.
A capital add-on, a permission condition, a change requirement and reversion to a formula are legally distinct instruments whose availability depends on the relevant regime. They should not be merged into a generic label of 'supervisory adjustment.' A proportionate response relates the nature and materiality of deficiencies to the reliability of the prescribed capital calculation and the protection of policyholders.
Revision of the European framework
The legally important temporal boundary is clear. Directive (EU) 2025/2 requires Member States to transpose amendments by January 29, 2027 and apply them from January 30, 2027. The EIOPA Solvency II overview confirms the effective timeline. The research cutoff of November 14, 2026 precedes that application date.
Specific technical guidance illustrates the problem of forward citation. EIOPA's revised dynamic-volatility-adjustment opinion is intended to apply on January 30, 2027; the preceding opinion continues until then. Likewise the revised supervisory-review guidelines have a future application date. A scientific manuscript should distinguish what has already been enacted, what becomes applicable later and what depends on national transposition or implementing measures. Treating a forthcoming standard as present operative law would misstate the approval test as of the research date.
Supervisory systems evolve as new asset structures, climate-related hazards, digital underwriting methods and group risk concentrations create new challenges. A robust model program should maintain a dated legal register of regulatory changes, assign responsible analysts and examine whether the changes affect governance, valuation and calibration. Legal horizon scanning does not itself authorize a model modification.
Integrated Analysis and Research Implications
Three distinct questions behind a reported SCR
The research supports an important analytical distinction. First, a numerical question: is the model a defensible estimate of the legally specified loss distribution under its data, assumptions and uncertainty? Second, an institutional question: do the insurer's governance, validation, data controls and documentation sustain the calculation as exposures and conditions change? Third, a legal question: has the competent supervisor authorized this exact modeling perimeter under the law currently in force? A favorable answer to one question does not establish the other two.
This distinction is a synthesis of existing requirements rather than a new regulatory test. It follows from the separate obligations in the statutory SCR definition, the validation obligation and the approval procedure. It helps interpret evidence without replacing the requirements themselves. One may have a mathematically consistent capital estimate built on incorrect exposure data; a well-run model excluded from permission; or an approved model later undermined by changed business and tail dependence.
Evidence hierarchy and negative findings
Some evidence bears directly on regulatory compliance: signed approval scope, model-change policy, board records, reproducible input/output sets, validation results, disclosed limitations and supervisory correspondence. Other evidence supports technical plausibility: external studies, benchmark results, academic papers on forecasting and historical loss databases. The types of evidence are complementary but have different authority. A peer-reviewed backtesting paper cannot amend the legal definition of SCR; a regulation establishing the SCR cannot prove that a particular stochastic loss engine is accurate.
Negative findings should be recorded as scientific results. An unreplicated component, unexplained P&L residual, fragile dependence assumption or failed stress diagnostic is evidence about model reliability even when no immediate quantitative correction can be estimated. Credible capital reporting includes the scope, magnitude where measurable, control implications and remediation date of each finding. Concealing failure within a single aggregate metric reduces both scientific transparency and supervisory usefulness.
Prudential costs of false confidence
Model error can create regulatory undercapitalization through underestimated tail loss, excessive diversification or optimistic recoveries. Excessively conservative assumptions can also distort business decisions, reduce capacity and misallocate capital. The social purpose of approval is therefore not mechanical minimization of capital or a blanket preference for conservatism. It is justified, reproducible and continually governed measurement compatible with policyholder protection. The economic cost of errors may be asymmetric, especially when insolvency impairs policyholders and public confidence, but the suitable response still depends on legal instruments and evidentiary strength.
Limits of comparative findings
The EU has a defined authorization route for full and partial internal models. The UK uses its own PRA permission system after Solvency UK reform. U.S. state RBC is structurally different. IAIS principles provide a supervisory common language. This variation limits any claim of universal regulatory procedure. The comparative conclusions are about institutional functions—risk representation, evidence, approval authority, continuing validation and intervention—not about the identity of national legal instruments.
Further empirical research could use anonymized supervisory applications and decisions, long-run model-change records, cross-firm output benchmarking, stress-event loss attribution and validation remediation histories. Confidentiality, survivor bias and changing regulatory versions would require explicit research designs. This monograph has undertaken no such firm-level empirical study and makes no claim that its examples predict real insurer outcomes.
Conclusion
Internal-model approval and regulatory validation join insurance mathematics with legally accountable supervision. The model translates uncertainty about future basic own funds into a capital measure; validation examines whether its distribution, inputs and operational implementation remain defensible; governance ensures that the information affects actual decisions; and supervisory authorization determines whether its use is legally permissible for the particular insurer and scope.
The central quantitative insight is that the far tail of an annual loss distribution cannot be established by a small record of realized exceptions. Risk dependence, data relevance, scenario design and the behavior of the economic balance sheet can materially affect the capital figure even when conventional summary statistics appear stable. P&L attribution, independent challenge, reproducibility, benchmark comparisons and reverse stress testing provide complementary information about mechanisms and omitted risks.
The central institutional insight is that authorization carries continuing obligations. Documented use, board understanding, risk-sensitive validation, cumulative model-change control and credible supervisory intervention maintain the connection between a permitted model and the insurer's actual risks. The legal comparison establishes that the EU's approval procedure, the UK's PRA permissions, U.S. RBC and IAIS supervisory standards must be read as distinct regimes.
As of November 14, 2026, EU reforms that apply from January 30, 2027 must be identified as forthcoming. The underlying analytical conclusion is durable: regulatory recognition of an insurance internal model rests on a traceable chain linking capital definition, statistical evidence, institutional accountability and a jurisdictionally valid authorization decision. This monograph documents that chain through existing law and scholarship without proposing a new theory or claiming insurer-specific empirical validation.
References
European Parliament and Council (2009). Directive 2009/138/EC, Article 101, Calculation of the Solvency Capital Requirement. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2188_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 112, General Provisions for Approval of Full and Partial Internal Models. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2199_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 113, Specific Provisions for Approval of Partial Internal Models. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2200_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 120, Use Test. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2207_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 121, Statistical Quality Standards. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2208_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 122, Calibration Standards. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2209_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 123, Profit and Loss Attribution. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2210_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 124, Validation Standards. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2211_en
European Parliament and Council (2009). Directive 2009/138/EC, Article 125, Documentation Standards. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-2212_en
European Commission (2015). Commission Implementing Regulation (EU) 2015/460 Establishing Implementing Technical Standards with Regard to the Procedure Concerning Approval of an Internal Model. https://eur-lex.europa.eu/eli/reg_impl/2015/460/oj/eng
European Commission (2014/2015). Commission Delegated Regulation (EU) 2015/35, Article 241, Model Validation Process. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-5900_en
European Commission (2014/2015). Commission Delegated Regulation (EU) 2015/35, Article 242, Validation Tools. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-5901_en
European Commission (2014/2015). Commission Delegated Regulation (EU) 2015/35, Article 243, General Documentation Provisions. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-5902_en
European Commission (2014/2015). Commission Delegated Regulation (EU) 2015/35, Article 244, Minimum Documentation Content. https://www.eiopa.europa.eu/rulebook/solvency-ii-single-rulebook/article-5903_en
European Parliament and Council (2009). Directive 2009/138/EC on the Taking-Up and Pursuit of the Business of Insurance and Reinsurance, Articles 115–119. https://eur-lex.europa.eu/eli/dir/2009/138/oj/eng
EIOPA (2026). Internal Models: Supervisory Convergence and Comparative Studies. https://www.eiopa.europa.eu/browse/supervisory-convergence/internal-models_en
PRA (2024). SoP3/24: Solvency II Internal Models—Permissions and Ongoing Monitoring, Current November 2024 Version. https://www.bankofengland.co.uk/prudential-regulation/publication/2024/february/solvency-ii-internal-models-permissions-and-ongoing-monitoring-sop
PRA (2024). SS1/24: Expectations for Meeting the PRA’s Internal Model Requirements for Insurers under Solvency II. https://www.bankofengland.co.uk/prudential-regulation/publication/2024/february/expectations-for-meeting-the-pra-internal-model-requirements-ss
PRA (2024). SS17/16: Solvency II Internal Models—Assessment, Model Change and the Role of Non-Executive Directors, November 2024 Version. https://www.bankofengland.co.uk/prudential-regulation/publication/2016/solvency2-internal-models-assessment-model-change-and-the-role-of-non-executive-directors-ss
NAIC (2026). Risk-Based Capital, Regulatory Background, Updated June 30, 2026. https://content.naic.org/insurance-topics/risk-based-capital
IAIS (2024). Insurance Core Principles and Common Framework for the Supervision of Internationally Active Insurance Groups, December 2024. https://www.iaisweb.org/uploads/2024/12/IAIS-ICPs-and-ComFrame-adopted-in-December-2024.pdf
European Parliament and Council (2025). Directive (EU) 2025/2 Amending Solvency II, Official Journal 2025. https://eur-lex.europa.eu/eli/dir/2025/2/oj/eng
EIOPA (2025). Final Report on Revised Opinion on Internal Models with Dynamic Volatility Adjustment—Solvency II Review. https://www.eiopa.europa.eu/publications/final-report-revised-opinion-internal-models-dva-solvency-ii-review_en
Kupiec (1995). Techniques for Verifying the Accuracy of Risk Measurement Models, The Journal of Derivatives 3(2), 73–84. https://doi.org/10.3905/jod.1995.407942
Christoffersen (1998). Evaluating Interval Forecasts, International Economic Review 39(4), 841–862. https://doi.org/10.2307/2527341
EIOPA (2026). Revised Guidelines on the Supervisory Review Process, February 13, 2026. https://www.eiopa.europa.eu/publications/revised-guidelines-supervisory-review-process_en
EIOPA (2026). Solvency II: Regulation and Policy Overview. https://www.eiopa.europa.eu/browse/regulation-and-policy/solvency-ii_en
EIOPA (2026). Final Report on Revised Guidelines on Group Solvency—Solvency II Review, July 15, 2026. https://www.eiopa.europa.eu/publications/final-report-revised-guidelines-group-solvency-solvency-ii-review_en